Dominant-negative suppression of HNF-1 alpha results in mitochondrial dysfunction, INS-1 cell apoptosis, and increased sensitivity to ceramide-, but not to high glucose-induced cell death. by Wobser, Hella et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Physiology and Medical Physics Articles Department of Physiology and Medical Physics
1-1-2002
Dominant-negative suppression of HNF-1 alpha
results in mitochondrial dysfunction, INS-1 cell
apoptosis, and increased sensitivity to ceramide-,
but not to high glucose-induced cell death.
Hella Wobser
Westphalian Wilhelms-University
Heiko Düssmann
Westphalian Wilhelms-University
Donat Kögel
Westphalian Wilhelms-University
Haiyan Wang
University Medical Center, Geneva
Claus Reimertz
Westphalian Wilhelms-University
See next page for additional authors
This Article is brought to you for free and open access by the Department
of Physiology and Medical Physics at e-publications@RCSI. It has been
accepted for inclusion in Physiology and Medical Physics Articles by an
authorized administrator of e-publications@RCSI. For more information,
please contact epubs@rcsi.ie.
Citation
Wobser H, Düssmann H, Kögel D, Wang H, Reimertz C, Wollheim CB, Byrne MM, Prehn JH. Dominant-negative suppression of
HNF-1 alpha results in mitochondrial dysfunction, INS-1 cell apoptosis, and increased sensitivity to ceramide-, but not to high
glucose-induced cell death. Journal of Biological Chemistry. 2002;277(8):6413-21.
Authors
Hella Wobser, Heiko Düssmann, Donat Kögel, Haiyan Wang, Claus Reimertz, Claes B. Wollheim, Maria M.
Byrne, and Jochen HM Prehn
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/physiolart/83
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/physiolart/83
Dominant-negative Suppression of HNF-1 Results in Mitochondrial
Dysfunction, INS-1 Cell Apoptosis, and Increased Sensitivity to
Ceramide-, but Not to High Glucose-induced Cell Death*
Received for publication, August 30, 2001, and in revised form, October 30, 2001
Published, JBC Papers in Press, November 27, 2001, DOI 10.1074/jbc.M108390200
Hella Wobser‡, Heiko Du¨ßmann‡, Donat Ko¨gel‡, Haiyan Wang§, Claus Reimertz‡,
Claes B. Wollheim§, Maria M. Byrne¶, and Jochen H. M. Prehn‡¶**
From the ‡Interdisciplinary Center for Clinical Research (IZKF), Research Group “Apoptosis and Cell Death,” the
¶Department of Pharmacology and Toxicology, Westphalian Wilhelms-University, D-48149 Mu¨nster, Germany, and the
§Department of Internal Medicine, Division of Clinical Biochemistry and Experimental Diabetology, University Medical
Center, CH-1211 Geneva, Switzerland
Maturity onset diabetes of the young (MODY) 3 is a
monogenic form of diabetes caused by mutations in the
transcription factor hepatocyte nuclear factor (HNF)-
1. We investigated the involvement of apoptotic events
in INS-1 insulinoma cells overexpressing wild-type
HNF-1 (WT-HNF-1) or a dominant-negative mutant
(DN-HNF-1) under control of a doxycycline-dependent
transcriptional activator. Forty-eight h after induction
of DN-HNF-1, INS-1 cells activated caspase-3 and un-
derwent apoptotic cell death, while cells overexpressing
WT-HNF-1 remained viable. Mitochondrial cytochrome
c release and activation of caspase-9 accompanied DN-
HNF-1-induced apoptosis, suggesting the involvement
of the mitochondrial apoptosis pathway. Activation of
caspases was preceded by mitochondrial hyperpolariza-
tion and decreased expression of the anti-apoptotic pro-
tein Bcl-xL. Transient overexpression of Bcl-xL was suf-
ficient to rescue INS-1 cells from DN-HNF-1-induced
apoptosis. Both WT- and DN-HNF-1-expressing cells
demonstrated similar increases in apoptosis when cul-
tured at high glucose (25 mM). In contrast, induction of
DN-HNF-1 highly sensitized cells to ceramide toxicity.
In cells cultured at low glucose, DN-HNF-1 induction
also caused up-regulation of the cell cycle inhibitor
p27KIP1. Therefore, our data indicate that increased sen-
sitivity to the mitochondrial apoptosis pathway and de-
creased cell proliferation may account for the progres-
sive loss of -cell function seen in MODY 3 subjects.
Maturity onset diabetes of the young (MODY)1 is a mono-
genic form of diabetes characterized by early age of onset (25
years), autosomal dominant transmission, and primary pancre-
atic -cell dysfunction (1). It has been postulated that it may
account for 1–5% of all diabetes. It results from heterozygous
mutations of at least six different genes, one encoding for the
glycolytic enzyme glucokinase (MODY2) and the others encod-
ing transcription factors hepatocyte nuclear factor (HNF)-4
(MODY1), HNF-1 (TCF1; MODY3), insulin promoter factor-1
(IPF-1; MODY4), HNF-1 (TCF2; MODY5), and NeuroD/2
(MODY6). MODY3 is the commonest form of MODY accounting
for 65% of MODY cases in the United Kingdom (2).
Phenotypically, most MODY 3 subjects under the age of 10
years have normal glucose tolerance (2). However, studies in
the prediabetic phase show that insulin secretion is reduced
only when plasma glucose concentrations exceed 8 mM (3).
Similar patterns of insulin secretion are seen in MODY 1
subjects (4) as well as in partially pancreatectomized rats and
dogs (5, 6) suggesting that a reduction in -cell mass may be
contributing to the observed -cell dysfunction.
HNF-1 is a dimeric homeodomain-containing protein that
is expressed in the liver, kidney, intestine, and pancreatic islets
(7–9). It is involved in the regulation of hepatic proteins as well
as proteins affecting carbohydrate metabolism and fatty acid
homeostasis (10–13). HNF-1 gene mutations are found in the
promoter region, DNA-binding domain, and transactivation
domain, and lead to a loss of function. Some mutants such as
the most frequently found P291fsinsC also act as dominant-
negative proteins in vitro, i.e. they retain their DNA-binding
domain and form nonfunctional dimers with wild-type HNF-1
(14, 15). Considerable variation also exists in the severity of the
diabetes (2, 16), with 30% of MODY3 subjects eventually
requiring insulin therapy.
Homozygous HNF-1 knockout mice develop diabetes with
defective insulin secretory responses to glucose and arginine
(11, 12) but normal responses to KCl (17). These mice also
demonstrated an inadequate -cell mass for the degree of hy-
perglycemia, as well as a reduction in the ratio of - to non-
cells. Principally, a defect in -cell mass compensation can be
caused by decreased neogenesis/proliferation rate, increased
apoptosis rate, or both (18). Reduction in -cell mass has been
observed in several NIDDM animal models (19–24). There is
strong evidence supporting the increase in -cell apoptosis as a
predominant factor resulting in decrease in -cell mass (19, 21,
25–27).
This study was therefore undertaken to establish whether
HNF-1 function plays a role in the control of apoptosis in
insulin secreting cells, and thereby the pathogenesis of MODY3
diabetes. This study demonstrates that dominant-negative
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suppression of HNF-1 function in INS-1 insulinoma cells ac-
tivates the evolutionary conserved apoptotic cell death machin-
ery via alterations in gene expression and mitochondrial func-
tion, and increases their sensitivity to ceramide-, but not to
high glucose-induced apoptosis.
EXPERIMENTAL PROCEDURES
Materials—N-Acetyl-D-erythrosphingosine (C2-ceramide) and stau-
rosporine (STS) were purchased from Alexis (Gru¨nberg, Germany).
C2-dihydroceramide was from Biomol (Hamburg, Germany), and doxy-
cycline from Sigma (Deisenhofen, Germany). The broad spectrum
caspase inhibitor Z-Val-Ala-Asp(O-methyl)-fluoromethylketone (zVAD-
fmk) was obtained from Enzyme Systems (Dublin, CA). The caspase
substrate acetyl-Asp-Glu-Val-Asp-aminomethylcoumarin (Ac-DEVD-
AMC) was purchased from Bachem (Heidelberg, Germany). All other
chemicals came in analytical grade purity from Promega (Mannheim,
Germany) or Roth (Karlsruhe, Germany).
Cultivation and Treatment of Insulinoma Cells Overexpressing
HNF-1 in an Inducible System—Rat INS-1 insulinoma cells overex-
pressing wild-type HNF-1 (number 15) (WT-HNF-1) or a dominant-
negative mutant of HNF-1 (SM6, number 31; DN-HNF-1) under
control of a doxycycline-dependent transcriptional activator have been
described previously (28). The SM6 mutant contains a substitution of 83
amino acids in the HNF-1 DNA-binding domain, resulting in the
formation of non-functional heterodimers with wild-type HNF-1 (29).
The level of HNF-1 expression can be tightly controlled by culturing
the cells over defined time periods with doxycycline (28). Maximal
induction of HNF-1 is achieved at a concentration of 500 ng/ml (28).
INS-1 cells conditionally overexpressing WT-HNF-1 and DN-HNF-1,
as well as parental INS-1 cells were cultured in RPMI 1640 medium
(Invitrogen, Germany) supplemented with 2 mM L-glutamin, 1 mM
pyruvate, penicillin (100 units/ml), streptomycin (100 g/ml), 10% fetal
calf serum (PAA, Co¨lbe, Germany), 10 mM Hepes (pH 7.4), and 50 M
2-mercaptoethanol. Cells were plated at a density of 6  104 cells/cm2.
After 36 h, culture medium was supplemented with 500 ng/ml doxycy-
cline for 6–60 h to induce the expression of WT- and DN-HNF-1,
respectively. In the experiments shown in Fig. 6A, the doxycycline
treatment was performed in the presence of varying glucose concentra-
tions (0–25 mM). In the experiments shown in Fig. 6, B–D, WT- or
DN-HNF-1 expression was induced for 14 or 24 h in RPMI 1640
medium, and cells were treated during the last 4 h with C2-ceramide,
C2-dihydroceramide, or vehicle (dimethyl sulfoxide, 0.1%).
Hoechst Staining of Nuclear Chromatin and Evaluation of Cellular
Necrosis—To observe nuclear changes indicative of apoptosis, the chro-
matin-specific dye Hoechst 33258 was used. Cultures were fixed with
4% paraformaldehyde in phosphate-buffered saline (PBS) at 37 °C for
10 min, then permeabilized by treatment with a 19:1 mixture of etha-
nol/acetic acid at 20 °C for 15 min. Cells were stained with 1 g/ml
Hoechst 33258 (Sigma) in PBS at room temperature for 20 min. Hoechst
staining was viewed with an Eclipse TE 300 inverted-stage fluorescence
microscope (Nikon, Du¨sseldorf, Germany) with the following optics:
excitation, 340–380 nm; dichroic mirror, 400 nm; emission, 435–485
nm. Digital images of equal exposure were acquired using a 12-bit CCD
camera (SPOT-2 camera; Diagnostic Instruments, Sterling Heights,
MI) and SPOT software version 2.2.1. Uptake of the membrane-imper-
meant dye propidium iodide (5 g/ml) was used for the detection of
cellular necrosis (optics: excitation 510–560 nm; dichroic mirror, 575
nm; emission, 590 nm).
Measurement of Caspase Activity—Cells were lysed in 200 l of lysis
buffer (10 mM Hepes, pH 7.4, 42 mM KCl, 5 mM MgCl2, 1 mM phenyl-
methylsulfonyl fluoride, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothre-
itol, 1 g/ml pepstatin A, 1 g/ml leupeptin, 5 g/ml aprotinin, 0.5%
CHAPS). Fifty l of this lysate was added to 150 l of reaction buffer (25
mM Hepes, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, 3 mM dithiothreitol,
pH 7.5). The reaction buffer was supplemented with 10 M Ac-DEVD-
AMC, a fluorigenic substrate cleaved by caspase-3, but also by other
executioner caspases including caspase-6 and -7 (30). Accumulation of
AMC fluorescence was monitored over 120 min using a HTS fluorescent
plate reader (PerkinElmer Life Sciences, Langen, Germany) (excitation
380 nm, emission 465 nm). Fluorescence of blanks containing no cell
lysate were subtracted from the values. Protein content was determined
using the Pierce Coomassie Plus Protein Assay Reagent (KMF, Cologne,
Germany). Caspase activity is expressed as change in arbitrary fluo-
rescent units (A.U.) per g of protein and hour.
Quantification of Mitochondrial Membrane Potential—The mito-
chondrial membrane potential was quantified confocally using an in-
verted Olympus IX70 microscope attached to a confocal laser scanning
unit equipped with a 488 nm argon laser and a 60 oil fluorescence
objective (Fluoview; Olympus, Hamburg, Germany). Cells were culti-
vated in 8-well chambered coverglasses (Nalge Nunc, Wiesbaden, Ger-
many). After treatment with doxycycline, cells were incubated with 25
nM 5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolocarbocyanine
iodide (JC-1; Molecular Probes, Leiden, The Netherlands) in culture
medium at 37 °C for 1 h. The cationic dye JC-1 distributes accross the
plasma and mitochondrial membranes according to the Nernst equa-
tion. The fluorescence emission sprectrum exhibits a red shift due to
formation of J-aggregates in a concentration-dependent manner in hy-
perpolarized mitochondria (31). The slides were mounted onto a micro-
scope stage equipped with a temperature-controlled inlay (HT200,
Minitu¨b, Tiefenbach, Germany). To prevent evaporation the media was
covered with embryo-tested paraffin oil. Images were obtained using
Fluoview 2.0 software and Kalman averaged from two individual scans
for each time point. After background subtraction the fluorescence
intensity of J-aggregates (570 nm) was devided by the intensity of the
JC-1 monomers (510–540 nm) for each image. Quantitative analysis of
the images was performed using the UTHSCSA Image Tool Programm
(available from www.maxrad6.uthscsa.edu).
Detection of Cytochrome c Release—Selective plasma membrane per-
meabilization with digitonin was used to analyze the release of cyto-
chrome c from mitochondria into the cytosol (32). This method obviates
possible artifacts due to mechanical breakage of the outer mitochon-
drial membrane by Dounce homogenization. Culture plates with 106
cells per well were placed on ice. Cells were washed with ice-cold PBS
and subsequently incubated in 100 l of permeabilization buffer (210
mM D-mannitol, 70 mM sucrose, 10 mM HEPES, 5 mM succinate, 0.2 mM
EGTA, 100 g/ml digitonin, pH 7.2) for 5 min. The permeabilization
buffer was transferred to a reaction tube and centrifuged for 10 min at
13,000 g. The supernatant was transferred to a new reaction tube and
protein content was determined using the Pierce BCA Micro Protein
Assay kit. Equal amounts of protein were analyzed by Western blot
analysis using 15% SDS-PAGE as described below.
Total RNA Extraction and Northern Blot Analysis—DN-HNF1 cells
were cultured in the presence or absence of 500 ng/ml doxycycline for
48 h and continued for 8 h at the indicated glucose concentrations. Total
RNA was extracted by the guanidinium thiocyanate/phenol/chloroform
method. Total RNA (20 g) was denatured with glyoxal and dimethyl
sulfoxide and separated on 1% agarose gels. Resolved RNA was blotted
to nylon membranes (Hybond-N, Amersham Pharmacia Biotech) by
vacuum transfer (VacuGeneXL, Amersham Pharmacia Biotech), fol-
lowed by UV cross-linking. The membranes were prehybridized and
then hybridized to 32P-labeled random primed cDNA probes according
to standard protocols. cDNA fragments used as probes for cyclophilin,
Bcl-xL, Bax, Bad, Bid, p21, and p27 mRNA detection were prepared by
reverse transcriptase-PCR and confirmed by sequencing. HNF-1
cDNA was obtained from corresponding expression vector kindly pro-
vided by Dr. R. Cortese (Istituto Di Recerche Di Biologica Molecolare,
Pomezia, Italy).
Western Blotting—Cells were rinsed with ice-cold PBS and lysed in
Tris-buffered saline containing SDS, glycerin, and protease inhibitors.
Protein content was determined using the Pierce BCA Micro Protein
Assay kit. Samples were supplemented with 2-mercaptoethanol and
denaturated at 95 °C for 5 min. An equal amount of protein (20–50 g)
was separated with 5–15% SDS-PAGE and blotted to nitrocellulose
membranes (Protean BA 85; Schleicher & Schuell, Dassel, Germany).
The blots were blocked with 5% nonfat milk in blocking solution (15 mM
Tris-HCl, pH 7.5, 200 mM NaCl, and 0.1% Tween 20) for 2 h at room
temperature. Membranes were incubated overnight at 4 °C with the
following primary antibodies: a rabbit polyclonal anti-HNF-1 antibody
diluted 1:5,000 (kindly provided by Dr. R. Cortese), a mouse monoclonal
anti-cytochrome c antibody (clone 7H8.2C12, 1:1000, Pharmingen Bec-
ton Dickinson, Hamburg, Germany), a rabbit polyclonal anti-active
caspase-3 antibody (MF397) raised against p17/p12 x-ray crystallo-
graphic grade recombinant caspase-3 diluted 1:1,000 (33) kindly pro-
vided by Dr. D. W. Nicholson, Merck Frosst, Point Claire-Dorval, Que-
bec, Canada), a rabbit polyclonal anti-active caspase-9 antibody
(MF445) raised against the p18 large subunit diluted 1:1,000 (kindly
provided by Dr. Nicholson), and a mouse monoclonal anti--tubulin
antibody (clone DM 1A; 1:10,000, Sigma). Afterward, membranes were
washed and incubated with anti-mouse or anti-rabbit IgG-horseradish
peroxidase conjugate (1:1,000–1:5,000; Promega). Antibody-conjugated
peroxidase activity was visualized using the SuperSignal chemilumi-
nescence reagent (Pierce). Membranes were stripped in standard strip-
ping buffer (2% SDS, 62.5 mM Tris-HCl, 100 mM 2-mercaptoethanol, pH
6.8) at 60 °C for 30 min, washed twice and reprobed.
Immunofluorescence Analysis—Cells were fixed in 4% paraformalde-
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hyde solution, washed three times with PBS, permeabilized at room
temperature in PBS containing 0.15% Tween 20 for 20 min, and then
incubated with blocking solution (PBS with 8% bovine serum albumin
and 0.05% Tween 20) at room temperature for 30 min. Bcl-xL protein
was detected using a mouse monoclonal anti-rat Bcl-x antibody
(B22620, clone 4; Transduction Laboratories, Becton Dickinson, Lex-
ington, KY) diluted 1:200, Bim was detected using a rat monoclonal
anti-mouse Bim antibody recognizing BimEL, BimL, and BimS
(MAB17001, clone 14A8; Chemicon, Temecula, CA) diluted 1:100, Bax
was detected using a rabbit polyclonal anti-human Bax antibody rec-
ognizing active Bax (06-499; Upstate Biotechnology, Lake Placid, NY)
(34) diluted 1:500, and Bak was detected using a rabbit polyclonal
anti-human Bak antibody (sc-832, G-23; Santa Cruz Biotechnology,
Heidelberg, Germany) diluted 1:500. After incubation at room temper-
ature for 1 h, cells were washed and incubated with biotin-conjugated
goat anti-mouse or anti-rat IgG antibody (Vector Laboratories, Burl-
ingame, CA) diluted 1:1,000. The secondary antibody was detected
using Oregon Green-conjugated streptavidin (Molecular Probes) diluted
1:1,000. Rabbit polyclonal antibodies were detected using Texas Red-
conjugated goat anti-rabbit IgG (Molecular Probes), diluted 1:1,000.
Control cultures were incubated with secondary antibody only. Immu-
nofluorescence was viewed with the Eclipse TE 300 microscope with the
following optics: Oregon Green, excitation, 465–495 nm; dichroic mir-
ror, 505 nm; emission, 515–555 nm; Texas Red, excitation 510–560 nm;
dichroic mirror, 575 nm; emission, 590 nm. Digital images of equal
exposure were acquired using the SPOT-2 camera.
Transient Transfection Experiments—To generate pEGFP-C1-Bcl-
xL, the complete open reading frame of the human Bcl-xL gene (35) was
amplified with primers 5-TTAGATCTATGTCTCAGAGCAACCGG-
GAG-3 and 5-TTGAATTCGGTGGGAGGGTAGAGTGG-3 using Pfu
Polymerase (Promega). The obtained PCR product was digested with
BglII and EcoRI and cloned between the BglII and EcoRI sites of
pEGFP-C1 (CLONTECH, Palo Alto, CA). For transfections, INS-1 cells
were plated onto 24-well tissue culture plates. One day later cells were
transfected with plasmids pEGFP-C1-Bcl-xL or pEGFP-C1 using the F2
transfection reagent (Targeting Systems, Santee, CA). 300 ng of plas-
mid DNA and 0.3 l of F2 reagent were diluted in 200 l of RPMI
medium under serum-free conditions and preincubated at room tem-
perature for 20 min. Cultures were incubated with the DNA/F2-trans-
fection mixture at 37 °C for 1 h. After 24 h, the culture medium was
supplemented with 500 ng/ml doxycycline to induce DN-HNF-1 ex-
pression. After a further 48 h, nuclei were stained live with Hoechst
33258. Apoptotic nuclei and expression of Bcl-xL-EGFP and EGFP were
observed by epifluorescence microscopy as described above. In co-trans-
fection experiments, INS-1 cells were transfected with pEGFP-C1 (40
ng) and either pSFFV-Neo or pSFFV-Bcl-xL (280 ng) (35).
Statistics—Data are given as mean  S.E. For statistical compari-
son, ANOVA and subsequent Tukey’s test were employed. p Values
smaller than 0.05 were considered to be statistically significant.
RESULTS
INS-1 Cells Subjected to Prolonged Suppression of HNF-1
Function Undergo Apoptotic Cell Death—Using a reverse tet-
racycline-dependent transactivator system we have previously
shown that dominant-negative suppression of HNF-1 function
inhibits the expression of HNF-1 target genes involved in
glucose and lipid homeostasis (15, 28). In subsequent experi-
ments, we noted that under conditions of prolonged induction
of DN-HNF-1 (48 h), INS-1 cells frequently detached from
the substratum and floated in the culture medium. Floating
cells exhibited a round, shrunken morphology reminiscent of
apoptosis, suggesting that dominant-negative suppression of
HNF-1 may have also influenced the expression of genes
involved in the regulation of apoptosis. To investigate the re-
lationship between induction of DN-HNF-1 and alterations in
cell morphology in more detail, expression of WT-HNF-1 and
DN-HNF-1 was induced in INS-1 cells by treatment with
doxycycline for 6, 14, 24, 48, and 60 h. Apoptotic cell morphol-
ogy was assessed in parallel by Hoechst staining of nuclear
chromatin. Treatment with 500 ng/ml doxycycline led to a
rapid induction of WT-HNF-1 and DN-HNF-1 in INS-1 cells
stably transfected with the reverse tetracycline-dependent
transactivator system, displaying similar kinetics (Fig. 1, A
and B). In each case, significant induction was already evident
after 14 h of doxycycline treatment. Nuclei of non-induced
control cells exhibited a regular, oval shape and a septate
pattern of blue fluorescence (Fig. 1, C and D). The nuclear
morphology of INS-1 cells remained unchanged at 6 and 14 h
after induction of DN-HNF-1 (not shown). Twenty-four h after
doxycycline treatment, the majority of cells induced to overex-
press DN-HNF-1 also displayed regular nuclear Hoechst
staining and a normal cell morphology (Fig. 1D). Occasionally,
however, we detected cells with a typical nuclear apoptotic
morphology characterized by increased chromatin condensa-
tion and nuclear fragmentation. By 48 h, apoptotic nuclear
changes became visible in many DN-HNF-1-expressing INS-1
cells. By 60 h, non-apoptotic, apoptotic, late-stage apoptotic/
enucleated cells, as well as floating cells could be detected in
the cultures (not shown). Induction of WT-HNF-1 for 24, 48,
or 60 h, in contrast, did not lead to any significant changes in
nuclear morphology (Fig. 1C and data not shown). These re-
FIG. 1. Induction of DN-HNF-1 in-
duces apoptosis in INS-1 cells. Time
course of induction of WT-HNF-1 (A)
and DN-HNF-1 (B) in response to 500
ng/ml doxycycline. Fifty g of protein ex-
tract was separated by 10% SDS-PAGE,
proteins were blotted, and immunodetec-
tion was performed using an anti-HNF-1
antibody. Locations of molecular weight
marker bands (in kDa) are provided on
the left side of the figure. Membranes
were stripped and reprobed with an anti-
-tubulin antibody. Phase-contrast im-
ages and corresponding Hoechst 33258
staining of nuclei in INS-1 cells induced to
express WT-HNF-1 (C) or DN-HNF-1
(D) for 0, 24, and 48 h. Non-induced con-
trols show a smooth cell surface and a
septate pattern of blue Hoechst fluores-
cence. Note cell shrinkage, membrane
blebbing, and chromatin condensation
and fragmentation in cells overexpressing
DN-HNF-1. Scale bar  10 m.
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sults suggested that prolonged, dominant-negative suppression
of HNF-1 function is sufficient to trigger apoptosis in INS-1
cells.
Apoptotic Cell Death Induced by Dominant-negative Sup-
pression of HNF-1 Function Involves Activation of Executioner
Caspases—Caspases play a central role in the activation and
execution of apoptotic cell death. Based on their structure and
substrate specificity, caspases can be subdivided into three
subfamilies: (i) upstream or apical caspases containing a large
NH2-terminal region and specific motifs that are required for
their aggregation and autoactivation; (ii) downstream or effec-
tor caspases that are responsible for the execution of apoptotic
cell death; and (iii) caspases involved in the maturation of
pro-inflammatory cytokines (36). To assess whether activation
of executioner caspases was involved in DN-HNF1-induced
cell death, we measured caspase activity by monitoring the
cleavage of a fluorigenic caspase substrate by extracts from
doxycycline-treated INS-1 cells. Ac-DEVD-AMC is cleaved
most efficiently by caspase-3, the major executioner caspase in
most cell types, but also by other executioner caspases (30).
Production of the fluorescent cleavage product AMC was neg-
ligible with extracts from non-induced INS-1 cells equaling
3.55  0.35 A.U./g of protein and h (Fig. 2A). By 24 h of
induction of DN-HNF1-, there was a very moderate but sig-
nificant increase in cleavage activity to 7.21  0.71 A.U./g of
protein and h. By 48 h, caspase activity reached a maximum of
33.71  0.86 A.U./g of protein and h, an 10-fold increase
compared with non-induced control. Cleavage activity re-
mained elevated at 60 h of doxycycline treatment. In contrast,
induction of WT-HNF-1 for up to 60 h did not cause significant
caspase activity in the cultures (Fig. 2A), at any time point.
Parental INS-1 cells exposed to doxycycline also failed to ex-
hibit any increase in cleavage activity (Fig. 2A).
We also obtained direct evidence of caspase-3 activation by
Western blotting experiments. During apoptosis, caspase-3 is
proteolytically activated by cleavage of its 32-kDa precursor
into active subunits. We observed the appearance of the active
p17 subunit during the induction of DN-HNF-1 (Fig. 2B). In
contrast, the p17 subunit could not be detected after induction
of WT-HNF-1 (Fig. 2B). Both cell lines, however, were able
to activate caspase-3 in response to the apoptosis-inducing
protein kinase inhibitor, STS, a potent pro-apoptotic stimulus
(Fig. 2B).
Further evidence for the involvement of caspases in DN-
HNF-1-induced apoptosis was provided by examining the ef-
fect of the broad-spectrum caspase inhibitor, zVAD-fmk. A
simultaneous treatment with 100 M zVAD-fmk potently in-
hibited nuclear fragmentation examined 48 h after the induc-
tion of DN-HNF-1 (Fig. 2, C and D).
Activation of the Mitochondrial Apoptosis Pathway in DN-
HNF-1-induced Apoptosis: Mitochondrial Hyperpolarization
Precedes Cytochrome c Release—The release of pro-apoptotic
factors, such as cytochrome c, from the mitochondrial inter-
membrane space into the cytosol represents a central coordi-
nating step in apoptosis (37). Cytoplasmic accumulation of
pro-apoptotic cytochrome c induces a caspase activating, mul-
tiprotein complex, the apoptosome (38, 39). Evidence has been
provided that mitochondrial hyperpolarization is an early
event in trophic factor deprivation-, UV-, and STS-induced
apoptosis, preceding the release of pro-apoptotic factors such as
cytochrome c from mitochondria (40–44). We used the poten-
tial-sensitive probe JC-1 in combination with confocal laser
scanning microscopy to evaluate changes in mitochondrial
membrane potential during DN-HNF-1-induced apoptosis.
Twenty-four h after addition of doxycycline, mitochondrial hy-
perpolarization could be detected in the majority of INS-1 cells,
preceding the gross activation of executioner caspases (Fig. 3, A
and B). After 48 h of induction, cells with shrunken somata and
depolarized mitochondria could also be detected (Fig. 3A). This
finding is in agreement with previous studies showing that
mitochondria eventually depolarize after the release of cyto-
chrome c and activation of the caspase cascade (41, 45, 46). The
mitochondrial membrane potential of cells induced to overex-
press WT-HNF-1 did not change significantly up to 60 h after
onset of the doxycycline treatment (data not shown).
Mitochondrial hyperpolarization after induction of DN-
HNF-1 was followed by the release of the pro-apoptotic factor
cytochrome c from mitochondria (Fig. 3C). Using selective dig-
itonin permeabilization of the plasma membrane, cytosolic ac-
cumulation of cytochrome c could be detected after 48 and 60 h
of doxycycline treatment. No significant cytochrome c release
could be detected in cells expressing WT-HNF-1. After its
release into the cytosol, cytochrome c is capable of binding to
the apoptotic protease-activating factor 1 (39). This complex
activates procaspase-9 in the presence of dATP, resulting in
apoptosome formation and activation of executioner caspases
such as caspase-3 (38, 39). In agreement with previous reports
demonstrating significant autoactivation of procaspase-9 even
in unstimulated cells (47), non-induced controls exhibited de-
tectable levels of the active, large p18 subunit of caspase-9 (Fig.
3D). Induction of DN-HNF-1 led to signficant accumulation of
FIG. 2. Activation of caspases during DN-HNF-1-induced apo-
ptosis. A, time course of caspase-3-like protease activity in cytosolic
protein extracts. INS-1 cells were induced to overexpress WT-HNF-1
or DN-HNF-1 for 0, 24, 48, and 60 h. As a control, parental INS-1 cells
were exposed to doxycycline for up to 60 h. Caspase protease activity
was measured by cleavage of the fluorigenic substrate Ac-DEVD-AMC
(10 M). Activities are represented as increase in AMC fluorescence (in
A.U.) over 1 h per g of protein. Data are mean  S.E. from n  6
cultures. Experiments were repeated twice with similar results. Differ-
ent from non-induced controls: *, p  0.05. B, detection of the active
caspase-3 p17 subunit by Western blot analysis. As a positive control,
cells were exposed for 6 h to the apoptosis-inducing kinase inhibitor
STS (3 M). Membrane was stripped and reprobed with an anti--
tubulin antibody to prove equal loading of samples. A duplicate exper-
iment yielded comparable results. C, treatment with the broad-spec-
trum caspase inhibitor zVAD-fmk (100 M) inhibits chromatin
fragmentation after induction of DN-HNF-1. Cultures were simulta-
neously treated with doxycycline and zVAD-FMK or vehicle (dimethyl
sulfoxide; -zVAD-fmk). After 48 h, nuclei were stained with Hoechst
33258. Arrows indicate the presence of nuclear fragmentation. Scale
bar  20 m.
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the p18 active subunit after 48 and 60 h, while cells overex-
pressing WT-HNF-1 did not show such an increase (Fig. 3D).
Altered Gene Expression of Bcl-xL and p27KIP1 during Dom-
inant-negative Suppression of HNF-1 Function—Release of
pro-apoptotic factors from mitochondria requires a selective
outer membrane permeability increase that is triggered and
controlled by pro- and anti-apoptotic Bcl-2 family proteins (37).
We next investigated the expression of Bcl-2 family members
during DN-HNF-1-induced apoptosis. Bax is a pro-apoptotic
Bcl-2 family member believed to be a structural component of
the mitochondrial outer membrane release channel (37). Ex-
pression of bax mRNA was not altered 48 h after induction of
DN-HNF-1 (Fig. 4A). Moreover, bax gene expression was not
sensitive to alterations in glucose concentration, both in in-
duced and non-induced cells. Bax protein levels also remained
unchanged, and similar results were obtained with the pro-
apoptotic Bax homolog Bak (data not shown). Nevertheless, we
obtained evidence for Bax activation during DN-HNF-1-in-
duced apoptosis detected with a polyclonal antibody that rec-
ognizes a conformational change in Bax required for its pro-
FIG. 3. Mitochondrial membrane hyperpolarization and cyto-
chrome c release during DN-HNF-1-induced apoptosis. A, con-
focal JC-1 fluorescence images of INS-1 cells induced to express DN-
HNF-1 for 0, 24, or 48 h. The overlay of the two emission wavelengths
of the membrane potential-sensitive probe JC-1 shows a red shift in the
confocal scans between 0 and 24 h, indicative of mitochondrial hyper-
polarization. After 48 h, a heterogeneous state is detected with cells
exhibiting depolarized mitochondria (green fluorescence) or complete
loss of JC-1 fluorescence, and cells exhibiting hyperpolarized mitochon-
dria (yellow to red fluorescence). Scale bars: 50 m (upper panel) and 10
m (lower panel). B, quantification of JC-1 fluorescence changes. The
ratio of the red and green fluorescence emission was obtained from
three individual scans and calculated from n  210–273 cells. Different
from non-induced controls: *, p  0.05. The experiment was repeated
twice with similar results. C, cytochrome c release into the cytosol
during DN-HNF-1-induced apoptosis. INS-1 cells were induced to
overexpress WT- or DN-HNF-1 for 0, 24, and 48 h and were then
subjected to digitonin permeabilization of the plasma membrane (250
g/ml, 4 °C) for 5 min. Soluble cytochrome c was detected in the super-
natant by Western blot analysis. As a positive control, non-induced
INS-1 cells were exposed to STS (3 M, 6 h). Membrane was stripped
and reprobed with an anti--tubulin antibody to prove equal loading of
samples. The experiment was performed three times with similar re-
sults. D, detection of the active caspase-9 p18 subunit during DN-HNF-
1-induced apoptosis. A duplicate experiment yielded comparable
results.
FIG. 4. Altered expression of genes involved in apoptosis and
cell cycle regulation during DN-HNF-1-induced apoptosis. A,
Northern blot analysis of gene expression in DN-HNF-1 cells induced
with doxycycline for 48 h. Cultures were continued for 8 h at the
indicated glucose concentrations. After this period, total RNA was ex-
tracted and samples were hybridized with the indicated cDNA probes.
B, detection of Bax activation by immunofluorescence analysis using a
polyclonal antibody recognizing a conformational change in Bax re-
quired for its pro-apoptotic activity. INS-1 cells were induced to over-
express DN-HNF-1 in the presence of 12 mM glucose for 48 h or were
exposed to 3 M STS for 6 h. C, decrease in Bcl-xL protein expression
during DN-HNF-1-induced apoptosis detected by immunofluorescence
analysis using a monoclonal antibody. INS-1 cells were induced to
overexpress WT- or DN-HNF-1 for 48 h in the presence of 12 mM
glucose, both in the absence or presence of the caspase inhibitor zVAD-
fmk (100 M). Scale bar  10 m.
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apoptotic activity (Fig. 4B) (34). Bax activation could also be
detected in response to 3 M STS (Fig. 4B).
Of note, expression of the anti-apoptotic Bcl-2 family mem-
ber Bcl-xL decreased significantly after DN-HNF-1 induction
(Fig. 4A). Bcl-xL mRNA expression was regulated by glucose in
induced and non-induced cultures, with increasing levels at
increasing glucose concentrations. However, DN-HNF-1 ex-
pressing cells showed a decreased response to glucose for
Bcl-xL mRNA expression compared with non-induced cells.
The decrease in Bcl-xL expression upon induction of DN-
HNF-1 could also be detected on the protein level (Fig. 4C).
Cultures treated with the caspase inhibitor zVAD-FMK also
showed this decrease, suggesting that this was not due to
caspase-mediated degradation of Bcl-xL (48). Cells expressing
WT-HNF-1 did not exhibit a decrease in Bcl-xL expression
(Fig. 4C).
We next investigated the expression of pro-apoptotic Bcl-2
family members of the Bcl-2-homology domain BH3-only family
during the induction of DN-HNF-1. These proteins are be-
lieved to neutralize the anti-apoptotic activity of Bcl-2 and
Bcl-xL via direct protein-protein interactions, hence sensitizing
cells to Bax- or Bak-mediated cytochrome c release (49). The
expression of the BH3-only members Bad, Bid, and Bim re-
mained unchanged during the induction of DN-HNF-1 (Fig.
4A and data not shown). However, by a screen of other genes
involved in cell cycle and apoptosis regulation, we found that
induction of DN-HNF-1 also led to a dramatic increase in the
expression of the cell cycle inhibitor p27KIP1, most notable at
low glucose concentrations (Fig. 4A). Expression of p21WAF1, a
second cell cycle inhibitor and an important p53 target gene,
was slightly increased at the highest glucose concentration.
However, induction of DN-HNF-1 did not potentiate
p21WAF1 mRNA expression.
Overexpression of Bcl-xL Is Sufficient to Inhibit Apoptosis
Induction by DN-HNF-1—Evidence has been provided that
Bcl-xL inhibits cytochrome c release during apoptosis (40).
We were therefore interested to determine whether overex-
pression of Bcl-xL was able to reverse DN-HNF-1-induced
cell death. INS-1 cells were transfected with plasmids encod-
ing an EGFP-Bcl-xL fusion protein or EGFP alone (controls).
Twenty-four h after the transfection, expression of DN-
HNF-1 was induced for time periods of 48 and 60 h. Cells
were assessed for apoptosis by counterstaining with Hoechst
33258. Overexpression of EGFP-Bcl-xL potently inhibited apo-
ptosis induction in cultures exposed for 48 or 60 h to doxycy-
cline compared with the EGFP-transfected controls (Fig. 5).
Similar results were obtained in INS-1 cells transiently co-
transfected with the EGFP vector and either plasmid pSFFV-
Neo (controls) or pSFFV-Bcl-xL (apoptosis rate after 48 h:
6.5  1.5% in non-induced pSFFV-Neo-transfected cells,
3.0  1.8% in non-induced pSFFV-Bcl-xL-transfected cells,
72.3  2.9% in DN-HNF-1-expressing cells transfected with
pSFFV-Neo, and 21.2  5.4% in DN-HNF-1-expressing cells
transfected with pSFFV-Bcl-xL; n  3 cultures; a duplicate
experiment yielded comparable results).
DN-HNF-1 Sensitizes INS-1 Cells to Ceramide-, but Not to
High Glucose-induced Apoptosis—We were finally interested to
determine whether a transient inhibition of HNF-1 function
was sufficient to sensitize INS-1 cells to glucose- or ceramide-
induced apoptosis. In a first set of experiments, expression of
WT- or DN-HNF-1 was induced for 24 h in the presence of 0,
2, 5, 10, 17.5, or 25 mM glucose. After this time period, a
caspase activity assay was performed to quantify the activation
of executioner caspases. In both cell lines, exposure to 0 mM
glucose led to a significant increase in caspase activity com-
pared with cells cultured at 5 or 10 mM glucose (Fig. 6A).
However, the increase in apoptosis was potentiated in DN-
HNF-1-expressing cells. Exposure to high glucose (17.5 and
25 mM) did not induce apoptosis in either cell line.
In a second experiment, expression of WT- and DN-HNF-1
was induced for 48 h (Fig. 6A). Cells overexpressing WT-
HNF-1 showed increased apoptosis at 0 and 25 compared with
5 and 10 mM glucose. DN-HNF-1 expressing cells showed
significantly higher apoptosis activation at 2, 5, 10, and 17.5
mM glucose compared with WT-HNF-1-expressing cells. How-
ever, there was no statistically significant difference in the
extent of apoptosis induction by 25 mM glucose between WT-
and DN-HNF-1-expressing cells. DN-HNF-1-expressing
cells cultured at 0 mM glucose could not be analyzed after 48 h,
since most cells had already detached from the culture dish.
Ceramide toxicity has been shown to mediate fatty acid-
induced apoptosis in -cells (25, 50). We finally investigated the
effect of an exposure to C2-ceramide in WT- and DN-HNF-1-
expressing INS-1 cells (Fig. 6B). Cells were induced to express
WT- or DN-HNF-1 for 14 and 24 h. During the last 4 h, cells
were treated with 50 or 100 M C2-ceramide, and a caspase
activity assay was performed. Interestingly, exposure to 100
M C2-ceramide potently activated apoptosis in the cells over-
expressing DN-HNF-1 for 24 h. Pronounced activation of
caspases could already be detected in C2-ceramide-treated cul-
tures induced to overexpress DN-HNF-1 for 14 h. In contrast,
C2-ceramide only induced a very modest caspase activation in
cells overexpressing WT-HNF-1 for 24 h.
In a second experiment, we simultaneously determined nu-
clear apoptosis (Hoechst staining of nuclear chromatin) and
FIG. 5. Overexpression of Bcl-xL prevents DN-HNF-1-in-
duced apoptosis. A, Bcl-xL-EGFP or EGFP (control) were transiently
transfected into INS-1 cells by lipofection. After 24 h, expression of
DN-HNF-1 was induced for 48 h. Live cells were counterstained with
Hoechst 33258 and analyzed by epifluorescence and phase contrast
microscopy. Note the absence of chromatin condensation and fragmen-
tation in cells expressing Bcl-xL-EGFP. Scale bar  20 m. B, quanti-
tative analysis of nuclear apoptosis in Bcl-xL-EGFP- and EGFP-trans-
fected INS-1 cells induced to overexpress DN-HNF-1 for 48 or 60 h.
Non-induced cells served as controls. All GFP-positive cells per culture
(100 cells) were assessed for apoptotic nuclear morphology. Data are
mean  S.E. from n  5–6 cultures in three separate transfection
experiments. Different from respective non-induced controls: *, p 
0.05. Difference between Bcl-xL-EGFP- and EGFP-transfected cul-
tures: #, p  0.05.
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cellular necrosis (membrane leakage visualized by uptake of
the membrane-impermeant dye propidium iodide) in response
to C2-ceramide in living cells. Cells were induced to express
WT- or DN-HNF-1 for 24 h. C2-ceramide (100 M), the biolog-
ically less active C2-dihydroceramide (100 M), or vehicle was
added during the last 4 h. Exposure to C2-ceramide selectively
induced apoptosis in the DN-HNF-1-expressing cells (Fig. 6,
C and D). Control experiments using C2-dihydroceramide
showed that nonspecific detergent effects could be excluded.
DISCUSSION
The present study demonstrates several important findings
that may help in the understanding of -cell dysfunction in
subjects with MODY3. These include (i) prolonged suppression
of HNF-1 function is sufficient to activate the evolutionary
conserved apoptotic cell death program in insulin-secreting
cells; (ii) overexpression of DN-HNF-1 leads to decreased ex-
pression of the central survival protein Bcl-xL; (iii) sensitizes
the cell to ceramide-, but not to high glucose-induced apoptosis;
and (iv) leads to increased expression of the cyclin-dependent
kinase inhibitor p27KIP1.
HNF-1 has been shown to trans-activate the rat insulin I
gene promoter (9, 51). Overexpression of the SM6 and
P291fsinsC HNF-1 mutants in INS-1 insulinoma cells re-
sulted in impaired insulin gene transcription (15, 28). Similar
findings have been obtained by overexpression of a dominant-
negative mutant of HNF-4 (52). Interestingly, insulin tran-
scription is not completely suppressed in cells carrying a dom-
inant-negative or null HNF-1 mutation (12, 28), suggesting
that the insulin gene is also regulated by other transcription
factors (11). The expression of insulin-like growth factors I and
II is also reduced in HNF-1-deficient mice (12). Defective
insulin/insulin-like growth factor signaling through the PI 3-ki-
nase and Akt kinase pathway may play a prominent role in
DN-HNF-1-induced apoptosis. Akt kinase is able to phospho-
rylate and inactivate several pro-apoptotic proteins, such as
Bad and caspase-9 (53, 54). Other effects of PI 3-kinase and Akt
kinase include phosphorylation-dependent regulation of tran-
scription factors of the Forkhead and cAMP-response- element-
binding protein families, leading to reduced transcription of
pro- (55), and enhanced transcription of anti-apoptotic genes
(56, 57). Interestingly, the Forkhead transcription factor
FKHR-L1 has also been shown to down-regulate the expression
of the cell cycle inhibitor p27KIP1 in a PI 3-kinase-dependent
manner (58). Reduced insulin or insulin-like growth factor
signaling through PI 3-kinase could therefore also play a role in
the increase in p27KIP1 expression observed in the DN mutant
cells. The PI 3-kinase/Akt kinase pathway has also been impli-
cated in the activation of transcription factor nuclear factor-B
(NF-B) (59, 60). Binding sites for the active NF-B subunits
p65/relA and c-rel have been demonstrated by functional anal-
ysis of the bcl-x promoter (61, 62). It is therefore conceivable
that the reduction in Bcl-xL expression upon induction of DN-
HNF-1 is caused by reduced activation of the PI 3-kinase/Akt
kinase/NF-B pathway. Overexpression of Bcl-xL in INS-1 cells
potently inhibited DN-HNF-1-induced apoptosis, demonstrat-
ing the importance of Bcl-xL in maintaining -cell survival.
Bcl-xL inhibits apoptosis by preventing the release of pro-
apoptotic factors from the mitochondrial intermembrane space
into the cytosol (37). Bcl-xL may act to directly inhibit the
formation of a megachannel in the outer mitochondrial mem-
brane or may indirectly inhibit pore formation by neutralizing
pro-apoptotic BH3-only family members. Although we detected
Bax activation after the induction of DN-HNF-1, the expres-
sion of Bax and Bak, as well as the expression of the BH3-only
family members Bad, Bid, and Bim were unaltered. As a re-
duction in Bcl-xL expression may be per se sufficient to activate
apoptosis (63, 64), our data point to an important role for
HNF-1 in maintaining -cell viability. The survival-support-
ing role of HNF-1 may not be confined to -cells, as homozy-
gous HNF-1 knock-out mice also show increased degeneration
FIG. 6. DN-HNF-1 sensitizes INS-1 cells to ceramide, but not
to high glucose-induced cell death. A, expression of WT- or DN-
HNF-1 was induced in the presence of 0–25 mM D-glucose for 24 or
48 h. Cytosolic protein extracts were prepared and caspase-3-like pro-
tease activity was measured using the fluorigenic substrate Ac-DEVD-
AMC. Data are mean  S.E. from n  4 cultures. Difference in caspase
activity from corresponding cultures exposed to 10 mM glucose: *, p 
0.05. Difference between WT- and DN-HNF-1-induced INS-1 cells at
identical glucose concentrations: #, p  0.05. n.a., not analyzed. The
experiment was performed in duplicate with similar results. B, effect on
ceramide toxicity. Expression of WT- or DN-HNF-1 was induced for
either 14 or 24 h. During the last 4 h, the culture medium was supple-
mented with C2-ceramide or vehicle (dimethyl sulfoxide), and a caspase
activity assay was performed. Data are mean  S.E. from n  6
cultures. Different from non-induced controls: *, p  0.05. A duplicate
experiment yielded comparable results. C, expression of WT- or DN-
HNF-1 was induced for 24 h. During the last 4 h, the culture medium
was supplemented with 100 M C2-ceramide, 100 M C2-dihydrocer-
amide or vehicle (dimethyl sulfoxide). Cells were stained live with
Hoechst 33258 (detection of nuclear apoptosis) and propidium iodide
(detection of membrane leakage). A total of 120–150 cells were analyzed
per culture. Data are mean  S.E. from n  4 cultures. Different from
non-induced controls: *, p  0.05. D, nuclear morphology of C2-cera-
mide and C2-dihydroceramide-treated INS-1 cells visualized with
Hoechst 33258. Cells were treated as described in C. Scale bar, 10 m.
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of hepatocytes and defects in spermatogenesis (12). Moreover,
the pathophysiological hyperpolarization of mitochondria ob-
served after induction of DN-HNF-1 may also explain the
reduced ability of glucose to hyperpolarize mitochondria and
hence to stimulate and coordinate insulin secretion in these
cells (15, 28).
Both an elevated glucose concentration as well as increased
formation of free fatty acids have been suggested to contribute
to a pathophysiological decline in -cell mass by influencing
-cell proliferation and -cell apoptosis (25, 65, 66). Exposure
to high glucose has previously been shown to activate apoptosis
in cultured mouse, rat, and human islets (66, 67). Expression of
DN-HNF-1-induced apoptosis over a broad glucose range (2–
17.5 mM) compared with WT-HNF-1-expressing cells. How-
ever, a potentiating effect of high glucose was not obvious in the
DN-HNF-1-expressing cells. In contrast, there was reduced
apoptosis activation at 17.5 and 25 mM glucose. It is conceivable
that increased bcl-xL mRNA expression at high glucose con-
centrations exerted a protective effect in the DN-HNF-1 ex-
pressing cells.
WT-HNF-1-expressing cells also activated apoptosis at 25
mM glucose (Fig. 6A), as did parental INS-1 cells.2 There was no
statistically significant difference in the extent of apoptosis
activation at 25 mM glucose between WT- and DN-HNF-1-
expressing cells. Our data therefore suggest that high glucose
activates a cell death pathway that is not influenced by DN-
HNF-1. A recent study has shown that high glucose-induced
apoptosis involved the activation of the death receptor pathway
in -cells via up-regulation of Fas receptor expression and
activation of initiator caspase-8 (66). The activation of the
mitochondrial pathway was unimportant as cytochrome c re-
lease could not be detected in response to high glucose. As
shown in the present study, DN-HNF-1 activated the mito-
chondrial apoptosis pathway. Hence it is conceivable that high
glucose and expression of DN-HNF-1 induce distinct cell
death pathways.
In contrast, we observed a significant potentiation of zero
glucose and in particular ceramide-induced apoptosis after
overexpression of DN-HNF-1. These findings suggest that
these stimuli also induce the activation of the mitochondrial
apoptosis pathway. Indeed, it has previously been shown that
saturated fatty acids activate the mitochondrial apoptosis
pathway (65), and that maintenance of Bcl-2 expression res-
cued -cells from free fatty acid-induced apoptosis (25). C2-
ceramide has been shown to impair insulin-induced signal
transduction via the insulin-dependent membrane recruitment
of Akt kinase (68). It is therefore conceivable that C2-ceramide
and induction of DN-HNF-1 resulted in a potentiation of the
inhibition of a central survival pathway. These results are also
in accordance with the general role of HNF-1 in the control of
lipid metabolism, and the -cell protective effects of agents
such as thiazolidinediones that influence lipid metabolism in
animal models of NIDDM (25, 27, 69).
Previous studies in normal rats have demonstrated that a
96-h intravenous glucose infusion resulted in significant in-
creases in -cell mass due to neogenesis and hypertrophy (70)
(see also Ref. 26). Interestingly, we observed decreased expres-
sion of the cell cycle inhibitor p27KIP1 at higher glucose con-
centrations in non-induced INS-1 cells. This adaptive response
was still present, although reduced in cells overexpressing
DN-HNF-1. There is evidence for similar adaptive responses
in prediabetic MODY3 subjects. After a 42-h glucose infusion
resulting in mild hyperglycemia (7 mM), there was a 32%
increase in insulin secretion in MODY3 compared with control
subjects (3). This adaptive response may not only be caused by
an increase in -cell proliferation, but also by an increased
performance of individual -cells. Prediabetic subjects with
MODY 3 secrete adequate if not higher amounts of insulin at
glucose levels 8 mM (3) and may exhibit hyperexcitability to
sulfonylureas (71). Nevertheless, it is tempting to speculate
that mild hyperglycemia may to some extent exert protective
effects in cells overexpressing DN-HNF-1, by inhibiting
p27KIP1 induction and stimulating Bcl-xL expression. Over
time, however, accumulation of free fatty acids, increased cer-
amide generation, as well as additive effects of glucotoxicity
may render -cells more vulnerable to cell death. Likewise, in
the Zucker diabetic fatty rat, -cell proliferation compensates
for the increased -cell loss at a time when plasma glucose is
moderately elevated, but this compensation ultimately fails
and the plasma glucose levels increase further (27). An imbal-
ance between -cell death and neogenesis, in combination with
decreased -cell compensation for insulin resistance may even-
tually lead to diabetes in MODY3 patients.
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